Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on AxoGen, boosting the price target to $26.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors that highlight AxoGen’s strong financial performance and promising future prospects. The company reported impressive third-quarter results for 2025, with a 23.5% year-over-year revenue growth and a net income that surpassed expectations. This financial success is supported by the recognition of nerve allograft as a standard medical practice by several professional societies, which is expected to drive further adoption and revenue growth.
Additionally, AxoGen’s strategic market development efforts have expanded coverage and reimbursement, significantly increasing the number of covered lives and commercial payer coverage. The company’s revenue guidance for 2025 has been raised to $222.8 million, indicating at least 19% growth. Furthermore, the anticipated approval of the Avance Nerve Graft’s Biologics License Application by the FDA in 2025 could enhance market penetration and secure a 12-year exclusivity period in the U.S., bolstering AxoGen’s competitive position. These factors collectively contribute to the positive outlook and justify the Buy rating.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $34.00 price target.